Targeting RAS signalling pathways in cancer therapy

By Julian Downward. Nature Reviews. Cancer, 2003

3,332 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e79074ae462caf73fa7b506562d779afbcb1f70d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (2006, background): “Furthermore, constitutively active ras oncogenes (particularly k-ras ) are common in human solid tumours, including 90% of pancreatic, 45% of colorectal, and 30% of hepatocellular cancers (HCC), 35% of non-small-cell lung cancers (NSCLC), 15% of melanomas and 10% of kidney tumour”
Cell-free nucleic acids as biomarkers in cancer patients (2011, background): “Several therapeutic agents in clinical trials target the KRAS, BRAF, EGFR or p53 pathway”
MAP kinase signalling pathways in cancer (2007, background): “As the literature on MAPK pathways and cancer is huge and includes comprehensive recent reviews (Downward, 2003; Wellbrock et al., 2004; Kolch, 2005; Bradham and McClay, 2006; Galabova-Kovacs et al., 2006; Kohno and Pouyssegur, 2006; Torii et al., 2006), we will take the liberty of a more…”
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches (2012, background): “Consequently, SOS is recruited to the plasma membrane where RAS proteins (KRAS, NRAS and HRAS) are localized as a result of prenylation [10].”
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “9,10 RAF is highly conserved in mammals, and RAF mutations are associated with many human cancers, including melanoma, breast cancer, ovarian cancer, colon cancer, thyroid cancer, and prostate cancer.”
let-7 regulates self renewal and tumorigenicity of breast cancer cells. (2007, background): “Increased H-RAS (Downward, 2003) and HMGA2 (Langelotz et al., 2003) have been reported in breast cancer and correlate with poor prognosis.”
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis (2006, background): “gov/cancertopics/types/lung">lung and colon cancers, they are rarely found in glioblastomas; the opposite is true for PTEN mutation”
Urothelial tumorigenesis: a tale of divergent pathways (2005, background): “Because RTK–Ras pathway activation occurs in a wide range of human tumours, almost all the components of this pathway have been exploited as therapeutic target”
The return of metabolism: biochemistry and physiology of the pentose phosphate pathway (2014, background): “Several allelic variants of H6PDH mutations are known and result in hirsutism, oligomenorrhoea, obesity, acne and infertility (Jamieson et al., 1999; Draper et al., 2003; Lavery et al., 2008).”
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction (2009, neutral): “(Downward, 2003; Sharma and Settleman, 2007).”
Cancer genomics: from discovery science to personalized medicine (2011, background): “However, the complexities and challenges of exploiting the knowledge of a cancer gene in a clinically meaningful way are exemplified by decades of intense pharmaceutical efforts to inhibit the oncogenic RAS-MAPK pathway either directly at the level of RA”